Rare Cancer Day is an annual awareness day designed to focus a light on rare cancers and the issues facing people living with them. Spearheaded by the NORD Rare Cancer Coalition, which is composed of 27 rare cancer-specific member organizations, Rare Cancer Day is observed on September 30 to highlight the challenges that patients living …
Our 8th annual patient and family gathering has gone virtual! Whether it’s your first year or eighth year attending one of our get-togethers, these events are for you. Click on any of the session dates below to get more details about the agenda and register for the event. For events that already occurred, you can …
FCF is proud to announce that its strong financial health and ongoing accountability and transparency have earned a 100/100 rating from Charity Navigator’s new Encompass Rating System. This score designates FCF as an official “Give with Confidence” charity, indicating that our organization is using its donations effectively based on Charity Navigator’s criteria. Charity Navigator is …
Albert Einstein College of Medicine’s Dr. Francesco Juan Martinez Navarro has been awarded this prestigious three-year fibrolamellar (FLC) research fellowship. This is the fifth Cancer Research Institute (CRI) fellowship that FCF has funded in the past five years. Read about Francisco’s important focus to further advance FLC discoveries.
Help us improve! Please fill out this quick survey to provide feedback on how we can improve the website to better meet your needs…
In this study published in Cell Reports, FCF-funded researcher Praveen Sethupathy and his team at Cornell University have leveraged a novel genomics technology to uncover therapeutic vulnerabilities in fibrolamellar carcinoma. Collaborators on the study include FCF-funded John Scott and F. Donelson Smith at the University of Washington. The lead author is Tim Dinh, who recently …
April 21st was a red letter day for the fibrolamellar community. A patient at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University, Baltimore, MD received the initial treatment of the first experimental therapy aimed to directly target the primary molecular cause of fibrolamellar carcinoma (FLC)…
The emerging COVID-19 pandemic has created unprecedented global challenges. We know that for individuals with underlying conditions, including cancer, the situation may seem fraught with uncertainty. We urge patients and caregivers to reach out …
A new clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study asks if individuals can mount an effective immune response against FLC by specifically targeting the unique chimeric protein …